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Introduction 
  
 9 
I.1 A general view of sleep substances 
Sleep is an intensive anabolic state when bodies are carrying outgrowth and repair 
processes such as the formation of new bones, muscular, and nervous tissues. Most 
animals, including humans and other mammals, birds, a significant number of reptiles, 
amphibians, and fish do sleep (Vorster and Born, 2015). Sleep-wake cycle is known for 
regulating by two biological mechanisms in the body, which has a link and balance each 
other. This model is also cited as the two-process model of sleep-wake regulation.  
Circadian rhythm often referred to as Process C, controls the body’s internal processes 
and alertness levels, which is run by the internal biological or circadian clock. Sleep-
wake homeostasis, also known as Process S, is the generation of a homeostatic sleep 
drive by the accumulation of hypnogenic (sleep-inducing) substance in the brain 
(Borbély, 1982). Source of the need for sleep often referred, as “sleep drive” mainly 
remains uncertain in the neural and cellular basis. But it can be considered that a 
homeostatic pressure, which dissipates during sleep, builds up during the wake period. In 
1892, Rosenbaum, at the first time, reported that the role of humoral factors in the 
regulation of sleep (Rosenbaum, 1892). Following this first report, many researchers 
independently showed that the existence of sleep-promoting chemicals. Over the past 
century, several additional hypnogenic substances involved in the sleep homeostatic 
process have been identified including prostaglandin D2 (Qu et al., 2006a; Ueno et al., 
1982), cytokines (Krueger et al., 1984a), adenosine (Porkka-Heiskanen et al., 1997), 
anandamide (García-García et al., 2009a), and the urotensin II peptide (Huitron-Resendiz 
et al., 2005). 
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I.2 The role of adenosine in physiological systems 
Adenosine is a pervasive nucleoside that contributes to building blocks of the energy 
storage molecule, ATP and nucleic acids as well as a substrate for multiple enzymes, and 
most importantly is an extracellular modulator of cellular activity (Illes et al., 2000). 
Adenosine has been widely studied in various tissues after its first description in 1929 by 
Drury and Szent-Gyorgyi (Drury and Szent-Györgyi, 1929) There is a wide range of 
organ systems affected by the endogenous release of adenosine (Olah and Stiles, 1992). 
For instance, adenosine has an essential hyperpolarizing effect on the membrane potential 
of excitable cells, play an inhibition role in vascular smooth muscle cells of coronary 
arteries and neurons in the brain.  Adenosine mostly plays an inhibitory neuromodulator 
role, not a neurotransmitter. It is inhibiting the neuronal activity of excitatory neurons 
(e.g. glutamatergic and cholinergic) as well as inhibitory neurons (e.g. GABAergic). 
Adenosine increases potassium conductances while postsynaptically inhibiting neuronal 
activity(Porkka-Heiskanen et al., 2002). The formation of adenosine can be increased by 
numerous cellular process and in all parts of these cells (Rudolphi et al., 1992; Fredholm, 
1997; Ongini and Schubert, 1998; Von Lubitz, 1999; Latini and Pedata, 2001). 
Physiological level of adenosine relies on fundamental cell biology and independent 
neuron activation. Extracellular accumulation of adenosine highly correlated with the 
ration of oxygen decreases in the condition like hypoxia, ischemia, and hypo-perfusion 
(Winn et al., 1980; Van Wylen et al., 1986). Therefore, it has been considered as a self-
controlling mechanism of the cells in order to minimize the cell damage. It has been also 
suggested that extracellular adenosine level start to increase in response to prolonged 
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neuronal activity during prolonged wakefulness period in the related brain area (i.e. basal 
forebrain). Thus, sleep induced in order to keep energy balance of the brain before it 
affected. In conclusion, it hypothesized that local energy reduction in the basal forebrain 
area will induce increased extracellular adenosine level and sleep (Porkka-Heiskanen et 
al., 2002).  
 
I.2.1 Adenosine level and its regulation 
Adenosine monophosphate (AMP) and S-adenosylhomocysteine are the two well-known 
molecules that play the role in the formation of adenosine (Fredholm, 2007; Schrader, 
1983). The activity of the enzyme S-adenosylhomocysteine hydrolase on S-
adenosylhomocysteine forms adenosine.  It can also act to snare adenosine in the 
existence of excess L- homocysteine. This process appears intracellular level and it is the 
way that the enzyme bidirectional ensures the persistent presence of a finite concentration 
of adenosine in the cell. The intracellular adenosine kinase generates AMP from 
adenosine, which can generate by 5’ nucleotidase. This mutual activity keeps the constant 
presence of a predetermined intracellular level of adenosine in the range of 10 to a few 
hundred nanomolar (nM) under physiologic circumstances (Ballarín et al., 1991). 
Since all cells appear to possess one or more equilibrative purine transporters, the 
predetermined intracellular concentration of adenosine ensures that there is also a not 
insufficient extracellular concentration of adenosine. Releasing of adenine nucleotide is 
the main case for the increasing level of extracellular adenosine (Geiger and Fyda, 1991). 
The series of ectoenzymes on the cell surface forms extracellular adenosine by the 
conversion of ATP to adenosine. It has been reported that many cell types can release 
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extracellular ATP by various mechanisms, including co-release from storage vesicles 
together with other neurotransmitters, lysosome exocytosis, a “kiss and run” mechanism 
(MacDonald et al., 2006), release from inflammatory cells or vascular endothelial via 
connexin hemichannels and channels such as P2X7 receptors (Chen et al., 2006; Faigle et 
al., 2008; Linden, 2006), unrestrained leakage from necrotic cells (Eltzschig, 2009), and 
controlled release through pannexin hemichannels (Chekeni et al., 2010; Elliott et al., 
2009). AMP forms by breaking down of extracellular ATP and adenosine diphosphate 
(ADP) via multiple ectoenzymes, exclusively CD39 (Yegutkin, 2008). Ecto-5’-
nucleotidase, CD73 broken down formed AMP to adenosine is the only way in the 
brain(Resta et al., 1998). 
Essentially, the cell membrane breaking process results in an increased level of 
extracellular adenine.  Therefore, any form of the trauma is connected to elevate the level 
of adenine nucleotides. In addition, cellular apoptosis also results in direct releasing of 
AMP (Yamaguchi et al., 2014). 
Endothelial cells, astrocytes, and neurons are the reported sources for the releasing of 
ATP via many different mechanisms (Bodin and Burnstock, 1998; Guthrie et al., 1999; 
Fields and Stevens, 2000). It is hypothesized that extracellular adenosine originates from 
neurons and from adjacent non-neuronal cells like glial cells in the brain (Halassa et al., 
2007, 2009). For instance, it proposed that astrocytes are an important source of 
extracellular adenosine via gliotransmission (Halassa et al., 2009). Since CD73 enzyme 
degrades AMP to adenosine in the brain. It also reported that ATP released from neurons 
also contributes to extracellular adenosine production via the CD73 enzyme (Lovatt et al., 
2012; Wall and Dale, 2013). In the striatum, the reports showed that adenosine formed 
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via CD73 alternatively act at the A2A receptor as extracellular CD73 is selectively co-
expressed and is physically linked with A2A receptors in striatopallidal neurons (Ena et 
al., 2013; Augusto et al., 2013). Adenosine can also be arbitrated synaptic depression, 
which is independent of CD73 activity and not a result of neuronal or astrocytic ATP 
release but is because of the activation of postsynaptic neurons. Thus, it leads to a 
response mechanism that suppresses the excitatory transmission during prolonged 
activity (Lovatt et al., 2012).  
It also postulated that under physiologic conditions, for instance, those involved in sleep 
and wakefulness, adenosine is generated independently from the CD73 activity. 
Adenosine deaminase (ADA) acts as decreasing adenosine level particularly when 
adenosine levels are high.  On the other hand, adenosine kinase rapidly converts 
adenosine to AMP by phosphorylation in the cells. Extracellular adenosine level 
determines by the formation and removal process of its.  These levels are low and usually 
in the range between 30-300 nM under physiological conditions (Ballarín et al., 1991). 
Adenosine level goes 1 µM to several tens of µM under extreme conditions, such as 
strenuous exercise or mild hypoxia, and in severely traumatic situations, including local 
ischemia (Fredholm, 2007). 
One of the biggest challenges in today’s sleep research is to link adenosine levels to 
sleep. It because of adenosine levels rapidly change in both the blood and tissue upon 
sampling and tissue samples must be frozen within a second or less to preserve in vivo 
levels. Such rapid inactivation makes difficult to achieve accurate measurement of 
adenosine level with the techniques, such as microdialysis and electrochemical methods. 
Therefore, reported adenosine levels in sleep and wakefulness should be carefully 
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accepted.  
 
I.2.2 Adenosine Receptors 
 
There are four subtypes of adenosine receptors have been reported. These are G protein-
coupled A1, A2A, A2B, and A3 receptors (Fredholm et al., 2011). A1R, A3R are Gi couple 
receptors and activation of them inhibits the adenylyl cyclase, activates phospholipase C 
(PLC), opens several types of K
+ 
channels, and inactivates N-, P-, and Q- type Ca
2+ 
channels (Gerwins and Fredholm, 1992). On the other hand, A2AR and A2BR are Gs or 
Golf couple receptors and activation of them increases adenylyl cyclase activity, induces 
the formation of inositol phosphates, and activates protein kinase C. In addition, A1R and 
A3R activation decreases cyclic adenosine monophosphate (cAMP) level while A2AR and 
A2BR activation increases level of cAMP (Fredholm, 1995).  
While A2A receptors are located mainly in the nucleus accumbens, striatum, and olfactory 
bulb, A1 receptors are widely distributed in the central nervous system (Fredholm et al., 
2001). On the other hand, A2B receptors are also widely expressed, but generally at very 
low levels; whereas A3 receptors are expressed at moderate levels in the hippocampus and 
cerebellum (Yaar et al., 2005). There is growing body of reports indicate that the effects 
of adenosine on vigilance state are mediated through A1 and A2A receptors.  However, 
little is known about A2B and A3 receptors on vigilance state (Huang et al., 2011).  
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I.3 Investigating the functions of adenosine receptors  
 
I.3.1 Uncovering functions of adenosine receptors by receptor antagonists  
Selective pharmacological tools are the key point for evaluating in vivo action of the 
adenosine receptors. More than last two decades, agonist and antagonist molecules have 
been produced with high affinity and selectivity for the human variants of each of the 
four receptors by the medicinal chemists (Fredholm et al., 2011). While adenosine 
receptor antagonists have diverse structures, the most popular adenosine receptor agonists 
are derivative of purine nucleotides (Müller and Jacobson, 2011). There are many A2AR 
selective antagonists developed from different structural classes such as 8-(3-
chlorostyryl) caffeine, MSX-2, and its water-soluble pro-dugs MSX-3, SCH-58261, 
KW6002, and ZM-241385. Besides that, radioactive, and more recently fluorescent, 
ligands of adenosine receptors were also developed and introduced for drug screening 
and monitoring in vivo receptor residence in humans.   
Caffeine is the well-known nonselective adenosine receptor antagonist and widely 
consumed as an arousal-promoting psychostimulant. The daily-consumed dose of 
caffeine by the human produces its partial profound arousal effect at the range of 25-50% 
despite its weakly potent nonselective blockade of adenosine A1 and A2A receptors 
(Fredholm et al., 1999). Paraxanthine and theophylline, which are the metabolites of the 
caffeine (Arnaud, 2011), are more potent inhibitors to A1 and A2A receptors than caffeine. 
Thus, adenosine receptors blockade can be long lasting even caffeine elimination in the 
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central system.  
 
Since A2A receptors antagonist showed a very consistent and perfect safety profile in the 
clinical trials for Parkinson’s disease (PD), this provides an insight to the 
pharmacological control of the sleep-wake cycle by A2A receptors antagonists as well.  
 
I.3.2 Revealing functions of adenosine receptors by receptor knockouts and other genetic 
techniques 
 
Targeted deletion of specific exons on all four G-protein coupled adenosine receptors has 
been achieved to generate genetic knockout (KO) models. (Fredholm et al., 2004; Wei et 
al., 2011). On the contrary to the limitations of pharmacological control of adenosine 
receptors, adenosine receptors KO models provide a wide range of the information about 
the physiological functions of the adenosine receptors and its role on the sleep-wake 
cycle by targeting them in the defined cells population. For instance, A2AR KO models 
help to the researcher for overcoming the concerns on the specificity of adenosine 
receptors antagonists and it clearly demonstrated that sleep-promoting effects of the A2A 
receptors agonists and caffeine-induced arousal effects depend on the A2A receptors but 
not A1 receptors (Huang et al., 2005). Conditional KO of some adenosine receptors genes 
in specific brain regions (e.g., striatum versus forebrain) and cell-types (astrocytes versus 
neurons) achieved with Cre-loxP system (Fuller et al., 2015; Wei et al., 2011), provides 
the researcher to overcome essential limitations of global A1 and A2A receptor on 
confounding developmental effect and lack of cell-type specificity (Fredholm et al., 
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2004). Brain region-depended deletion of the A2A receptors in the forebrain (i.e. 
hippocampus, cortex, striatum) (Bastia et al., 2005; Yu et al., 2008) and local deletion of 
the A1 receptors in CA1 or CA3 neurons and A2A receptors in nucleus accumbens (NAc) 
has been achieved. Local injection of adeno-associated virus (AAV) which includes 
vectors that containing the Cre transgene into the brains of mice carrying loxP-flanked A1 
receptor (Scammell et al., 2003) or A2A receptor (Lazarus et al., 2011) genes is the key 
method to obtain local deletion of these receptors. Conditional KO strategy revealed the 
role of adenosine receptors on the sleep-wake cycle in the basal ganglia. Moreover, the 
advancement of AAV carrying short-hairpin RNA targeted to produce site-specific 
silencing of the A2A receptors revealed that arousal effect of caffeine is mediated by A2A 
receptors in NAc shell (Lazarus et al., 2011). In addition, recent advancement of the 
optogenetics based on the modulation of the local neuronal activity by using the 
genetically engineered optical switches (e.g., channelrhodopsin) (Boyden et al., 2005; 
Deisseroth, 2014; Yizhar et al., 2011) or chemogenetics to investigate G-protein signaling 
in freely behaving animals by designer receptors exclusively activated by designer drugs 
(DREAAD) (Farrell et al., 2013; Giguere et al., 2014) has enhanced our understanding of 
novel brain circuits essential the sleep-wake cycle (Fuller et al., 2015). Lately, 
researchers also developed a probe (optoA2A receptor) for specific optogenetic control of 
A2A receptor signaling (Li et al., 2016).  
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I.4 Adenosine and sleep 
 
I.4.1 Adenosine level during sleep and wakefulness 
Adenosine is a well-known marker for the energy deficiency; extracellular adenosine 
level increase by the reduction of ATP (Kalinchuk et al., 2003)and is highly associated 
with the sleep promotion (Porkka-Heiskanen et al., 1997). Adenosine has been reported 
high level during slow-wave sleep (SWS) than wakefulness in the solution collected 
numerous brain area of cats by in vivo microdialysis probe while their routine sleep-wake 
cycle (Porkka-Heiskanen et al., 1997, 2000). In addition, in vivo microdialysis 
experiments demonstrated that adenosine level of the basal forebrain increase double 
during prolonged wakefulness in compare to the beginning of the long-lasting 
wakefulness (Porkka-Heiskanen et al., 1997, 2000). 
Although more than a half-century past from discovery of the hypnotic effect of 
adenosine in mammalian brain (Feldberg and Sherwood, 1954), the brain cell types 
involved in sleep-inducing effects of the adenosine still not uncover. Theoretically, glial 
cells and neurons are the sources of the extracellular adenosine and ATP, which is 
quickly converted to the adenosine. In addition, genetic engineered mice studies showed 
that blocking ATP releases from astrocytes resulting in decreasing level of the 
extracellular adenosine (Pascual et al., 2005). Even though these manipulations do not 
change total amount of the SWS, REM, and wakefulness, they cause the reduction of 
slow-wave activity and rebound sleep after long-term sleep loss which is suggesting that 
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adenosine releasing from the astrocytes has the role on the sleep drive (Halassa et al., 
2009). However, exact sources of adenosine still not elucidated.  
Further reports such as the elimination of adenosine deaminase (ADA) for increasing 
extracellular level of adenosine in the central nervous system of rats was also confirmed 
REM, and SWS inducing effect of the adenosine (Radulovacki et al., 1983). 
It is well described that adenosine takes the sleep modulation role via A1 and A2A 
receptors in the brain. However, the importance of these receptors on sleep-wake 
regulation remains controversial (Basheer et al., 2004; Huang et al., 2007). Early 
pharmacological studies with non-selective A1/A2A receptor antagonist caffeine, 
alloxazine, and the A1 receptor antagonist 8-cylopenthyltheophylline showed that A1 
receptors might be more important in sleep-wake regulation than the A2A receptors (Virus 
et al., 1990). 
However, the limitations of the pharmacological studies such as differences in solubility 
of antagonists, neuropharmacodynamics, blood-brain barrier permeability, and most 
crucial “off-target” effects in a high dose of antagonists lead to the misinterpretation of 
data. Later reports demonstrated that A1 receptors activation induce sleep or wakefulness 
in a region-specific manner (Ochiishi et al., 1999; Reppert et al., 1991; Rivkees et al., 
1995). The advancement of the genetically engineering systems such as recombinant viral 
vectors delivery in the brain, transgenic animals, and evidence human studies clearly 
proof that crucial role of the A2A receptors in the regulation of sleep and wakefulness 
over the last decade (Holst and Landolt, 2015; Lazarus et al., 2013, 2012). 
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I.4.2 The role of A1 receptors in sleep/wake regulations 
Early studies showed that adenosine A1 receptors activation with the systematic or 
intracerebroventricular administration of A1 receptor agonist N6-cyclopentyladenosine 
induced the slow-wave activity of the brain’s electrical signals during SWS(Benington et 
al., 1995). However, the total amount of the SWS and REM sleep remained unchanged 
during the lateral ventricular administration of A1 receptors antagonist (Urade et al., 
2003). This suggests that A1 receptors activation has opposite sleep-wake inducing effects 
in different brain regions. For instance, adenosine activity at A1 receptors inhibiting the 
arousal active neurons in the basal forebrain (BF) such as substantia immoniata and 
horizontal limb of the diagonal band of Broca (Alam et al., 1999; Strecker et al., 2000). 
There are two ways reported that adenosine may promote sleep via A1 receptors; A1 
receptors mediated inhibition of glutamatergic signal to cortically projecting GABAergic 
and cholinergic neurons of the BF (Yang et al., 2013) and A1 receptors mediated 
suppression of orexin/hypocretin neurons in the lateral hypothalamus (Thakkar et al., 
2008).  
Adenosine deaminase (ADA) and histamine neurons expressing A1 receptors are 
predominantly localized in the TMN region suggesting that histaminergic arousal in the 
TMN actively regulated by adenosine. Indeed, further reports showed that bilateral 
injections of A1 receptors agonist or ADA inhibitor conformycin into the rat TMN 
robustly increase the amount of SWS (Oishi et al., 2008). These results demonstrate that 
endogenous adenosine suppresses the arousal effects of the histaminergic system via 
activation of A1 receptors in TMN (Thakkar, 2011). In contrast to the sleep-inducing 
effect of an A1 receptor in the TMN, activation of A1 receptor shows the wake-promoting 
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effect in the lateral preoptic area of the hypothalamus (Methippara et al., 2005). 
I.4.3 The role of A2A receptors in the sleep/wake regulation. 
Central administration of the highly selective and potent adenosine A2A receptor agonist, 
CGS 21680 robustly increase SWS and REM sleep in mice (Satoh et al., 1996; Urade et 
al., 2003). Later studies demonstrated that infusions of CGS 21680 into the BF dose-
dependently inhibit release of the histamine in both medial preoptic area and frontal 
cortex, and induce the release of GABA in the TMN of the hypothalamus, but not in the 
frontal cortex (Hong et al., 2005).  GABA antagonist picrotoxin perfusion to the TMN 
blocking CGS 21680 inhibiting histamine release, which is suggesting that adenosine A2A 
receptor agonist promote sleep by inhibiting the histaminergic system through an increase 
in GABA release in the TMN. 
Earlier reports suggested that sleep generated by activation of sleep-promoting neurons in 
VLPO together with suppression of histaminergic wake-promoting neurons in the TMN 
through galaninergic and GABAergic inhibitory projections (Sherin et al., 1998, 1996). 
VLPO neurons characterized as two different cell types according to their response to 
serotonin and adenosine by intracellular recording in rat brain slices. An A1 receptor 
agonist primarily inhibits VLPO neurons activity, which is inhibiting arousing 
neurotransmitters noradrenaline and acetylcholine. In addition, despite the serotonin 
inhibits type-1 neurons and activates type-2 neurons, adenosine A2A receptors agonist 
postsynaptically activates type-2, but not type-1 neurons in the VLPO. These findings 
suggesting that type-2 neurons have an important role in sleep-inducing, however, type-1 
neurons provide sleep consolidation since only the absence of inhibitory effects from the 
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arousal system make them activated (Gallopin et al., 2005).  
The c-fos expression of neurons is not only observed in the VLPO, but also within the 
medial portion the olfactory tubercle and the NAc shell after the administration of CGS 
21680 into the rostral BF (Satoh et al., 1999; Scammell et al., 2001). Surprisingly, direct 
perfusion of adenosine A2A receptor agonist into the NAc promotes SWS and REM sleep 
as 75% amount of sleep measured when it infused into subarachnoid space. These 
findings suggested that A2A receptors within or close to the NAc predominantly induce 
sleep (Satoh et al., 1999). In addition, experiments on global genetic KOs of the A1 and 
A2A receptors showed that arousal effects of the caffeine, non-selective adenosine 
receptor agonists, depend on the A2A receptors but not A1 receptors (Huang et al., 2005). 
Further studies by using advance site-specific gene manipulation techniques for 
generating conditional A2AR KO mice such as silencing A2AR expression via local 
infection with AAV carrying short-hairpin RNA of A2A receptor or Cre/lox technology 
provides wide range of information for the understanding specific role of A2A receptors in 
the basal ganglia (BG) (Lazarus et al., 2011). In addition, reports show that arousal 
effects of caffeine abolished in the absence of the A2A receptors in the NAc. This result 
suggests that adenosine tonically activate NAc neurons in the absence of the caffeine 
since adenosine A2A receptors abundantly express throughout the striatum, including 
NAc shell (Rosin et al., 1998; Svenningsson et al., 1999).  
These findings also suggest that adenosine activity on A2AR in the NAc suppress the 
arousal systems, which can be turned on with the antagonist effects of the caffeine. In 
addition, studies on dopamine D2 receptors (D2R) in the NAc revealed the opposite effect 
in sleep-wake regulation compare to the A2AR. For instance, deletion of the dopamine 
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transporter (DAT), which is responsible for removing dopamine from the receptor (Giros 
and Caron, 1993), increases wakefulness and reduces SWS. Later studies showed that 
activation of A2A receptors leads to deteriorating affinity of dopamine at D2 receptors 
with intra-membrane interactions. Thus, adenosine and antagonist would control medium 
spiny projections neurons in the striatum via A2A independently of D2 receptors (Aoyama 
et al., 2000; Chen et al., 2001). Moreover, the studies show that the sensitivity of caffeine 
stimulation and homeostatic response to sleep deprivation increased in the humans who 
have a genetic reduction of striatal DAT (Holst and Landolt, 2015). 
Adenosine-mediated modulation of sleep-wake cycle in NAc revealed the possibility of 
basal ganglia neurons roles in sleep-wake regulation (Lazarus et al., 2011, 2012). Broad 
variety of cognition, movement, and sleep-wake related disorders have link with BG 
dysfunction like Parkinson’s and Huntington diseases as well as lesions in the BG (Adler 
and Thorpy, 2005; Dale et al., 2004; Goodman and Barker, 2010; Obeso et al., 2000; 
Wetter et al., 2000). Time spent in wakefulness together with the fragmentation of both 
sleep and wakefulness showed a robust reduction after bilateral lesions of the neurons in 
the striatum or especially in the NAc by using the ibotenic acid (Qiu et al., 2010). Lesions 
in the globus pallidus and caudate-putamen alone promoted wake by 50% and sleep by 
10%, respectively (Qiu et al., 2010). 
On the other hand, the reports showed that dopamine D2 receptors are notably expressing 
in BG and complete deletion of them increases SWS and REM sleep with a dramatic 
decrease of SWS delta power and wakefulness (Qu et al., 2010). In addition, PD patients 
mainly use modafinil to treat their excessive sleepiness and reports showed that arousal 
effects of modafinil specifically mediated by D1 and D2 receptors, which makes D2 
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receptors primary important (Qu et al., 2008).  
These reports suggest that A2AR activation induced the activity of GABAergic output 
neurons in the striatopallidal circuits and consequently arousal network in the thalamus, 
brainstem, and hypothalamus and eventually the cerebral cortex are sustained tight 
inhibitory control. Indeed, transgenic expression of optogenetic tools channelrhodopsin 
and chemogenetics tools DREADD in mice via Cre-recombinase (expressed under the 
A2A receptor promoter) dependent AAV vectors microinjections, exclusively induced 
SWS during specific activation of striatopallidal neurons by light or the small molecule 
clozapine-N-oxide (Oishi et al., 2017). 
Furthermore, recent studies show that A2AR also have a role in REM sleep. For example, 
blocking A2AR expressing neurons in the olfactory bulb promotes REM sleep. This 
finding implied that the olfactory bulb is the crucial site for adenosine A2AR-depended 
REM sleep regulation (Wang et al., 2017). Surprisingly, patients with the REM sleep 
behavior disorder have impaired smell ability (Stiasny-Kolster et al., 2007).  
 
I.5 A2AR as therapeutic target  
Caffeine is one of the ingredients of the daily beverages such as coffee, tea, and coke, 
which make it one of the most consuming compounds. Early studies show that adenosine 
receptors are the major targets of caffeine that later identified as a non-selective 
adenosine receptors antagonist. Adenosine receptors are widely expressed in the body, 
which provides promising therapeutic targets in a wide range of conditions, including 
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cerebral and cardiac ischemic diseases, immune and inflammatory disorders, cancer, and 
sleep disorders. Therefore, medicinal chemists show enormous efforts to produce the 
considerable number of selective agonists and antagonist for the adenosine receptors 
(Jacobson and Gao, 2006). 
Adenosine A2AR receptor is a G-protein coupled receptor and it mediates their activity 
via Gs-protein in peripheral systems or Golf protein in the striatum. Activation of A2A 
receptors increases adenylyl cyclase activity. It has been reported that adenosine A2AR is 
involved in vasodilation in the aorta and coronary artery (Fredholm et al., 2001). 
Moreover, activation of A2AR results in tachycardic effects by centrally located receptors 
and hypotensive effects by peripheral receptors (Schindler et al., 2005). These findings 
increase the efforts for treating hypertension with adenosine A2AR agonist CGS 21680; 
however, due to its non-target effects, the clinical applications of it terminated in vivo 
studies.  
The effects of caffeine, a general adenosine receptors antagonist, in the central nervous 
system such as enhancement of awareness and learning lead to researchers to investigate 
selective adenosine receptors antagonists in the nervous system. These investigations 
revealed that adenosine A1R and A2AR involves in the effects of caffeine in the central 
nervous system (Solinas et al., 2005; Ledent et al., 1997a). Especially, deletion of A2AR 
by genetic engineering techniques elucidate caffeine mediates its behavioral stimulatory 
effects by adenosine A2AR and has a crucial role in sleep regulation (Fredholm et al., 
2004; Huang et al., 2005; Satoh et al., 1998).  Besides that, many reports indicate that 
lack of the dopamine release in the striatum caused some Parkinson’s diseases symptoms.  
Remarkably, evidence shows that the interaction between dopamine D2R and adenosine 
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A2AR is antagonistic in the striatum.  Striatum includes the neurons that co-expressed 
A2AR and D2R and heterodimerization of these two subtypes restrains D2R function 
(Fredholm et al., 2001; Ferre et al., 1991). Therefore, A2AR antagonist application 
thought to be an alternative solution for treatment of the Parkinson’s disease.  Later 
clinical studies revealed that KW-6002 (istradefylline), an A2AR antagonist, is a novel 
treatment for the Parkinson’s disease (Xu et al., 2005; Hauser et al., 2003; Weiss et al., 
2003). In addition, studies showed that A2AR agonist could play neuroprotection roles in 
some experimental conditions and cerebral hemorrhagic injury (Mayne et al., 2001).  
 
The reports demonstrate that ethanol increases brain levels of adenosine by inhibiting 
adenosine reuptake. Then, alcohol and adenosine interact synergistically with the 
activation of D2 receptors in median spiny neurons of the striatum/nucleus accumbens, 
unlike the antagonistic relationship between dopamine and adenosine. Since G-protein β 
and γ dimers inhibition reduces voluntary alcohol consumption, antagonize the synergism 
of the A2AR and D2R with a drug might be a solution for alcohol control (Nature review-
Kenneth). Also, a selective A2AR antagonist can show antidepressant effects (El Yacoubi 
et al., 2001).  
 
In addition, A2AR activation by an agonist can also show protection roles in the 
peripheral system such as kidney (Linden, 2005). Especially, ischemic injury in the 
kidney prevents by the A2AR in bone marrow-derived cells (Fredholm et al., 2001).  
Moreover, studies showed that activation of A2AR by selective agonist CGS 21680 
provide board spectrum anti-inflammatory activity in a model of allergic asthma in the 
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rat. These findings suggesting that A2AR agonist could be useful alternatives to 
glucocorticosteroids in the treatment of asthma (Fozard et al., 2002). However, later dose 
studies of GW328267, an A2AR agonist designed for intranasal administration was 
negative. Therefore, compound withdrew from the clinical testing (Selective A2a 
receptor agonists as inhibitors of cellular activation, 2000)  
 
Activation of A2AR via adenosine is almost found all immune cells, including 
lymphocytes, monocytes, macrophages, and dendritic cells (Sitkovsky et al., 2004) and it 
seems to attenuate inflammation and reperfusion injury in a selection of tissues. Reports 
show that A2AR importantly involved in the limitation and termination of the prolonged 
inflammation (Ohta and Sitkovsky, 2001).  
 
I.7 Objective and outline of the dissertation 
 
Insomnia is one of the most common sleep problems with an estimated prevalence of 10–
15% in the general population and 30–60% in the older population (Roth, 2007). The 
most widely prescribed agents for the treatment of insomnia are central nervous system 
depressants, known as benzodiazepines (BDZ) and non-BDZ, that enhance signaling of 
the inhibitory neurotransmitter γ-aminobutyric acid (Wafford and Ebert, 2008). These 
medications are, however, plagued by a wide range of adverse effects, including muscle 
relaxation, rebound insomnia, changes in appetite, next-day sedation, cognitive 
impairment, amnesic effects, and the development of drug tolerance and dependence 
(Aragona, 2000; Vgontzas et al., 1995). In addition, orexin receptor antagonists have 
most recently been developed and approved as a medication for insomnia treatment (Cox 
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et al., 2010). The major issues of these drugs are, however, next-morning sleepiness with 
possible signs of muscle weakness, weird dreams, sleepwalking, other nighttime 
behaviors or suicidal ideation (Jacobson et al., 2014). Moreover, because orexin receptor 
antagonists mostly work by preventing arousal from sleep, they are widely inefficient in 
people who have problems falling asleep. 
 
CGS 21680, a highly selective adenosine A2A receptor (A2AR) agonist, produces 
profound increases in sleep after infusion into the subarachnoid space underlying the 
ventral surface region of the rostral basal forebrain in rats or into the lateral ventricle of 
mice (Satoh et al., 1999; Scammell et al., 2001; Urade et al., 2003). However, it is 
commonly believed that administration of an A2AR agonist has no clinical potential for 
treating sleep disorders because of its cardiovascular effects, including hypotension and 
tachycardia (de Lera Ruiz et al., 2014). Selective physiologic A2AR responses may, 
however, be evoked by a positive allosteric modulator, because its action, in contrast to 
an agonist, is limited to when and where adenosine is released. Adenosine levels in the 
brain are elevated during sleep (Porkka-Heiskanen et al., 1997) and thus, allosteric 
modulation may be an alternative strategy for the treatment of insomnia. In this study, we 
identified a positive allosteric modulator for A2AR, termed A2AR PAM-1, induces slow-
wave sleep (SWS) in mice without affecting body temperature and cardiovascular 
function. 
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Chapter 1 
 
 
 
An identification of adenosine A2AR positive allosteric modulator by small-molecule 
compounds screening  
 30 
 
1.1 Introduction 
Adenosine A2A receptors are the member of the G-protein coupled receptors family and 
coupling with Gs protein. Activation of A2AR induces synthesis of the secondary 
messenger; cyclic amino monophosphate (cAMP). We established mouse A2AR 
expressing Chinese hamster ovary cells (CHO) by using retroviral methods for screening 
small molecules from Nagase laboratory compounds library at the International Institute 
for Integrative Sleep Medicine, University of Tsukuba. High throughput screening 
revealed an adenosine A2AR positive allosteric modulator. Then, series of experiments 
were conducted to investigate allosteric characteristic of this modulator.  
 
1.2 Materials and Methods 
 
1.2.1 Mouse A2AR-expressing CHO cells 
The flag epitope tagged open reading frame of A2AR was amplified by PCR from mouse 
brain total RNA.  The resultant amplicon was cloned into a pMXs-IRES-Puro retroviral 
vector (Kitamura et al., 2003). Subsequently, this plasmid was transfected into the 
retrovirus packaging cell line Plat-E (Morita et al., 2000). The supernatant of transfected 
Plat-E cells was recovered after 24h and applied to Chinese hamster ovary (CHO) cells 
strongly expressing the ecotropic receptor for the retrovirus (Montminy et al., 1990). 
Mouse A2AR-expressing CHO (mA2AR-CHO) cells were selected in Dulbecco's modified 
eagle medium (DMEM) supplemented with 5% fetal bovine serum (FBS) and 1% 
nonessential amino acids (NEAA) by treatment with hygromycin B (250 μg/ml) and 
puromycin (10 μg/ml). The mA2AR-CHO cells were subsequently maintained in DMEM 
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supplemented with 5% FBS, 1% NEAA, 1% penicillin/streptomycin, 250 µg/ml 
Hygromycin B at 37 °C in an atmosphere of 5% CO2. 
 
1.2.2 cAMP assay 
Activation of A2AR was quantified by cyclic-adenosine monophosphate (cAMP) 
accumulation in CHO cells expressing mouse A2AR. CHO cells were suspended in 
Hanks’ balanced salt solution (HBSS) containing 1 M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 0.25 M IBMX (3-isobutyl-1-methylxanthine) in 384-well 
micro-plates (2×10
3
 cells per well) and incubated with adenosine, CGS 21680, A2AR 
PAM-1 at indicated concentrations for 30 min at 25
o
C. The detection mixture containing 
Eu-cAMP tracer and ULight-anti-cAMP antibody was added and incubated for 1h at 
25
o
C.  Micro-plate reader (ARVOX5; excitation: 340 nm; emission: 665 nm) was used to 
measure Forster resonance energy transfer (FRET) signal. All experiments were done 
under the guidelines of the manufacturer’s instruction. (LANCE Ultra cAMP Kit, 
PerkinElmer). The cAMP levels are based on the dynamic range (“linear portion”) of the 
cAMP standard curve and normalised to the baseline or adenosine treated group. 
 
1.2.3 Synthesis of A2AR PAM-1  
A solution of 2,3,4-fluorobenzoic acid (1.35 g, 7.68 mmol), 2-fluoro-4-iodoaniline (1.91 
g, 8.06 mmol), and lithium amide (0.702 g, 30.6 mmol) in tetrahydrofuran (10.5 mL) was 
reacted using a standard method (Cai et al., 2008) to give 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid [A2AR positive allosteric modulator (PAM)-1, 2.99 g, 
99%] as a brown solid (Figure 1.6); IR (KBr) 3311, 1673, 1602, 1520, 1500, 1444, 1273, 
768 cm
-1
; 
1
H NMR (400 MHz CD3OD) δ = 7.89 (1 H, ddd, J = 2.3, 6.0, 9.2 Hz), 7.48 (1 
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H, dd, J = 1.8, 10.5 Hz), 7.41 (1 H, ddd, J =1.4, 1.8, 8.5 Hz), 6.91 (1 H, ddd, J = 7.3, 9.4, 
9.4 Hz), 6.75 (1 H, ddd, J = 5.6, 8.5, 8.5 Hz); 
13
C NMR (100 MHz acetone-d6) δ = 169.9, 
155.7 (dd, JC,F = 252.1, 4.8 Hz), 155.6 (d, JC,F = 252.1 Hz), 143.6 (dd, JC,F = 247.8, 14.9 
Hz), 137.4 (dd, JC,F = 7.7, 2.9 Hz), 135.0 (d, JC,F = 3.8 Hz), 131.9(d, JC,F = 11.5 Hz), 
129.8 (dd, JC,F = 9.6, 3.8 Hz), 125.8 (d, JC,F = 21.0 Hz), 123.8 (d, JC,F = 5.8 Hz), 116.4, 
110.1 (d, JC,F = 18.2 Hz), 84.7 (d, JC,F = 6.7 Hz); HRMS-ESI: m/z [M-H]
-
 calcd for 
C13H6F3INO2, 391.9395; measured, 391.9414. 
 
 
 
1.3 Results 
 
1.3.1 Establishment of mA2AR expressing Chinese hamster Ovary (CHO) cells 
We established CHO cells that express mouse A2AR by a retrovirus mediated gene 
transfer method (Figure 1.1) (Kitamura et al., 2003). We then decided to use two 
thousands mA2AR-CHO cells per well for further compounds screening test after 
checking the baseline cAMP level of the different cell numbers by using the förster 
resonance energy transfer (FRET) immunoassay (Figure 1.1A). In addition, we observed 
increased level of the cAMP in mA2AR-CHO cells after treatment with different 
adenosine concentrations and also mA2AR expression in CHO cells were checked by 
quantitative polymerase chain reactions (QPCR) (Figure 1.1B, C). These experiments 
revealed that mA2AR highly expressed in CHO cells and they significantly responded to 
adenosine treatment.  
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1.3.2 Screening of small-molecule compounds for allosteric A2AR modulation 
Subsequently, we used these mA2AR-CHO cells to screen 1173 small-molecule 
compounds for their allosteric effects at A2ARs. The compounds were synthesized in Dr. 
Hiroshi Nagase’s laboratory at the University of Tsukuba. A2AR activity in CHO cells 
was determined by measuring cyclic adenosine monophosphate (cAMP) level after the 30 
min incubation with adenosine and small-molecule compounds using förster resonance 
energy transfer immunoassay. Initially, we tested 391 mixtures that had 3 compounds 
each in a primary screening. The results show that eight mixtures significantly enhanced 
the adenosine effects at A2AR (Figure 1.2).  
 
 
1.3.3 Positive allosteric effects of A2AR PAM-1 on mA2AR-CHO cells 
Further individual testing of the compounds 370, 371, and 372 in mixture 124 revealed 
that only compound 371 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid) in 
mixture 124 enhanced adenosine-induced A2AR activation (Figure 1.3A). A cell culture 
bioassay revealed that cAMP levels were not altered by treating A2AR-expressing or 
native CHO cells with compound 371 in the absence of adenosine or by treating native 
CHO with adenosine and compound 371  (Figure 1.3B), suggesting that compound 371 
is likely a positive allosteric modulator for A2AR and thus, we named this compound 
A2AR PAM-1 (Figure 1.3A).  
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1.3.4 Allosteric modulation of A2AR by A2AR PAM-1 
Co-treatment of A2AR-expressing CHO cells with 150 µM adenosine and different 
concentrations of A2AR PAM-1 (i.e., 25, 50, and 100 µM) amplified adenosine A2AR-
evoked cAMP accumulation in a dose-dependent manner by 42 % ± 1.4, 46 % ± 1.1, and 
50 % ± 1.0, respectively (Figure 1.4A).  Similarly, co-treatment of A2AR-expressing 
CHO cells with 100 µM A2AR PAM-1 and 50, 100, or 150 nM adenosine increased A2AR 
activity in the CHO cells in a dose-dependent manner by 55 % ± 0.4, 66 % ± 1.5, and 72 
% ± 1.7, whereas 100 µM A2AR PAM-1 did not significantly enhance the cellular activity 
of A2AR-expressing CHO cells treated with 250 nM adenosine (Figure 1.4B). 
Surprisingly, co-treatment of mA2AR-CHO cells with 100 µM A2AR PAM-1 and different 
concentrations of the highly selective A2AR agonist CGS 21680 did not increase the level 
of the cAMP (Figure 1.5). 
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Figure 1.1 Characterization of mouse A2AR-expressing CHO cells.  
(A) Cell number-dependent FRET activity of mA2AR-expressing CHO. (B) Dose-
dependent changes of FRET activity in mA2AR-expressing CHO after adenosine 
administration. (C) Expression of Chinese hamster adenosine receptors in mA2AR-
expressing (left panel) and native (right panel) CHO cells.  
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Figure 1.2 High-throughput screening of small-molecule compounds 
Changes of cAMP levels in CHO cells after treatment with adenosine and compound 
mixtures are shown as percentage of cAMP levels in CHO cells after treatment with 
adenosine. Experiments were performed in triplicate wells for each condition and 
repeated at least twice. **P < 0.01, compared with adenosine, assessed by unpaired two-
tailed Student’s t-test. 
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Figure 1.3 Co-treatment of mA2AR-CHO cells with A2AR PAM-1 and adenosine 
revealed an allosteric modulation 
(A) FRET activity in mA2AR-expressing CHO after treatment with adenosine and small 
molecule compounds 370, 371, or 372.  (B) FRET activity in mA2AR-expressing (left 
panel) and native (right panel) CHO cells after treatment with adenosine or adenosine and 
A2AR PAM-1, respectively. Experiments were performed in triplicate wells for each 
condition and repeated at least twice. Data are presented as the mean ± SEM. **: p<0.01 
compared with adenosine, assessed by unpaired Student’s t-test. 
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Figure 1.4 Allosteric modulation of A2AR by A2AR PAM-1 
Dose-dependent changes of cAMP level in mA2AR-expressing CHO cells after treatment 
with adenosine and different concentrations of A2AR PAM-1 (A) or A2AR PAM-1 and 
different concentrations of adenosine (B). Experiments were performed in triplicate wells 
for each condition and repeated at least twice. Data are presented as the mean ± SEM.    
*: p<0.05, **: p<0.01 compared with adenosine, assessed by unpaired Student’s t-test.  
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Figure 1.5 A2AR PAM-1 does not enhance A2AR activity in the presence of A2AR 
agonist CGS 21680. 
Changes of cAMP levels in mA2AR-expressing CHO cells after co-treatment with A2AR 
PAM-1 and different concentrations of A2AR agonist CGS 21680. Data are presented as 
the mean ± SEM. **: p<0.01 compared with CGS 21680 alone, assessed by unpaired 
Student’s t-test. 
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Figure 1.6 Chemical synthesis of A2AR PAM-1. 
A2AR PAM-1 (3) was produced by combining 2,3,4-fluorobenzoic acid (1) and 2-fluoro-
4-iodoaniline (2). 
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1.4 Summary & Conclusions 
Small molecules screening by using mouse A2AR (mA2AR) expressing CHO cells 
revealed a positive allosteric modulator for adenosine A2AR, denoted A2AR PAM-1. 
Further cell culture experiments showed that A2AR PAM-1 dose-dependently enhanced 
the activity of adenosine at A2AR. The enhancement activity of A2AR PAM-1 did not 
observe the high concentration of adenosine treatment (i.e. 250 nM). In addition, A2AR 
PAM-1 did not enhance the activity of A2AR potent agonist CGS 21680. This result 
indicates that CGS 21680 may block the binding site of A2AR PAM-1 at A2A receptor.  
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Chapter 2 
 
Intraperitoneal administration of A2AR PAM-1 effects on slow-wave sleep in mice   
 43 
 
2.1 Introduction 
Since cell culture experiments revealed an adenosine A2AR positive allosteric modulator  
(A2AR PAM-1) and it has known that central stimulation of A2AR induces slow-wave 
sleep, we then decided to test sleep-inducing effects of the A2AR PAM-1 in mice. Sleep 
bioassay was used to analyze wake, SWS, and REM sleep periods of the mice after 
intraperitoneal administration of adenosine A2AR allosteric modulator. In addition, we 
conducted a dose dependency test for A2AR PAM-1 and analyzed the sleep architecture 
after the i.p. administration of A2AR PAM-1 in mice.  
 
2.2 Materials and Methods 
 
2.2.1 Animals 
Male mouse lines on a C57BL/6 background, including wild-type and A2AR KO (Chen et 
al., 1999) mice, which were maintained at the International Institute of Integrative Sleep 
Medicine and weighing 21-27 g (10-15 weeks old), were used in the experiments. The 
animals were housed in an insulated and soundproof recording chamber that was 
maintained at an ambient temperature of 23 ± 0.5°C with a relative humidity of 50 ± 5% 
and an automatically controlled 12 h light/12 h dark cycle (light on at 8:00, illumination 
intensity ≈ 100 lux). All animals had free access to food and water. This study was 
performed in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the US National Institutes of Health (2011). Experimental 
protocols were in compliance with relevant Japanese and institutional laws and guidelines 
and approved by the University of Tsukuba animal ethics committee (protocol #14-322). 
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Every effort was made to minimize the number of animals used as well as any pain and 
discomfort experienced by the animals 
 
2.2.2 Stereotaxic surgery for placement of EEG/EMG electrodes  
Mice were anesthetized with pentobarbital [50 mg·kg
-1
, intraperitoneal (i.p.)] and then 
placed in a stereotaxic apparatus. Electroencephalogram (EEG) and electromyogram 
(EMG) electrodes for polysomnographic recordings were chronically implanted in the 
mice (Oishi et al., 2016). The implant comprised two stainless steel screws (1 mm in 
diameter) inserted through the skull above the cortex (anteroposterior, +1.0 mm; left-
right, -1.5 mm from bregma or lambda) according to the atlas of Paxinos and Franklin 
(Paxinos and Franklin, 2004) that served as the EEG electrodes. Two insulated, stainless 
steel Teflon-coated wires were placed bilaterally into both trapezius muscles and served 
as the EMG electrodes. All electrodes were attached to a micro connector and fixed to the 
skull with dental cement. 
2.2.3 Vigilance state assessment based on EEG/EMG polygraphic recordings 
Ten days after surgery, the mice were individually housed in transparent barrels in an 
insulated soundproof recording chamber and connected to the EEG-EMG recording 
cables for 3 to 5 days of habituation before starting the polygraphic recordings. To 
evaluate the spontaneous sleep-wake cycle, each animal was recorded for 24 h beginning 
at 20:00, the onset of the dark period. The animals then entered the pharmacologic phase 
of the study in which sleep-wakefulness parameters were recorded for 36 h. The data 
collected during the first 24 h also served as baseline comparison data for the second 
experimental day. Cortical EEG/EMG recordings were amplified, filtered (EEG 0.5-30 
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Hz; EMG 20-200 Hz), and digitized at a sampling rate of 128 Hz, and then recording 
using data acquisition software SleepSign® (Kissei Comtec, Matsumoto, Japan). The 
vigilance states were classified offline in 10-s epochs into three stages, i.e., wakefulness, 
rapid eye movement (REM) sleep, and SWS by SleepSign® (ver 3.4) according to 
standard criteria (Oishi et al., 2016). As a final step, defined vigilance stages were 
examined visually, and corrected when necessary.  
 
2.2.4 Pharmacological treatment 
For control data, mice were injected with saline or vehicle (10 ml·kg
-1
 body weight, i.p.) 
at 22:00 or 21:30, respectively. A2AR PAM-1 was dissolved in saline immediately before 
use and administered intraperitoneally at 22:00 on the experimental day at a dose of 30, 
60, or 75 mg·kg
-1
. Mice were randomly assigned to groups that received control or drug 
injections.  
2.2.5 Formation of the sodium salt of A2AR PAM-1 
Aqueous sodium hydroxide (100 μM, 754 μL) was added to a stirred solution of A2AR 
PAM-1 (0.266 g, 75.4 mmol) in ethanol (20.0 mL) at 0°C. The mixture was stirred for 45 
min at room temperature and then concentrated in vacuo and freeze-dried. The residue 
was dissolved in water and filtered. The filtrate was freeze-dried to obtain the sodium salt 
of A2AR PAM-1 (0.265 g, 89%) as a gray solid (m.p. 290−291°C; Anal. Calcd for 
C13H6NO2·Na·1.5H2O: C, 35.32; H, 2.05; N, 3.17. Measured: C, 35.34; H, 1.91; N, 3.14). 
The sodium salt of A2AR PAM-1 was used for all in-vivo experiments.  
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2.3 Results 
 
2.3.1 Intraperitoneal administration of A2AR PAM-1 induces SWS in mice 
We then tested the effect of intraperitoneal administration of A2AR PAM-1 on the 
sleep/wake behavior of wild-type mice. We analyzed EEG and EMG recordings made 
after saline or A2AR PAM-1 injections during the dark period at 22:00, when mice 
usually spend most of their time awake. Whereas baseline sleep and wake of mice prior 
treatment was not significantly different between the saline and A2AR PAM-1 groups 
during the dark period (Figure S3), A2AR PAM-1 (75 mg·kg
-1
) increased SWS after the 
injections for the following 8 h (Figure 2.1A,B; Figure 2.2A ) 
 
The total amount of SWS was increased by 60.8 ± 11.4 min for 8 h with the highest dose 
of A2AR PAM-1 (i.e., 75 mg·kg
-1
) compared with saline treatment, whereas wakefulness 
was decreased by 59.2 ± 12.8 min (Figure 2.2B). Intraperitoneal injection of A2AR PAM-
1 did not significantly alter the REM sleep duration during the dark period compared with 
saline injection.  
 
2.3.2 Intraperitoneal administration of A2AR PAM-1 induces SWS in a dose 
dependent manner 
The A2AR PAM-1 dose-dependently increased SWS, which is also known as non-rapid 
eye movement (non-REM) sleep, the major part of sleep characterized by slow and high-
voltage brain waves, for up to 8 h (Figure 2.3A). To assess whether EEG activity was 
altered by A2AR PAM-1 administration, we compared the normalized EEG power 
spectrum of SWS in mice treated with saline or A2AR PAM-1 (Figure 2.3B). EEG 
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activity in the frequency range of 0.5–25 Hz during SWS was indistinguishable between 
A2AR PAM-1–induced and natural (saline injection) SWS. These data suggest that A2AR 
PAM-1 induced physiologic sleep rather than abnormal sleep. 
 
2.3.3 Intraperitoneal administration of A2AR PAM-1 effects on sleep architecture of 
mice  
Administration of A2AR PAM-1 (75 mg·kg
-1
, i.p.) to the mice did not significantly affect 
the episode numbers of SWS and REM sleep for 8 h in the dark period (Figure 2.4A). On 
the other hand, wake episode numbers lasting 120 to 239 s increased by 307% , wake 
episode numbers lasting 480 to 959 s and 960 to 1909 s decreased by 47% and 88%, 
respectively, compared with the saline injection. The mean duration of wake episodes 
decreased by 38% compared with saline, but the duration of the SWS and REM sleep 
episodes was not significantly different after A2AR PAM-1 (75 mg·kg
-1
, i.p.) 
administration (Figure 2.4B). A2AR PAM-1 (75 mg·kg
-1
, i.p.) also did not significantly 
affect the number of transitions between SWS, wake, and REM sleep (Figure 2.4C). 
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Figure 2.1 Intraperitoneal administration of A2AR PAM-1 induced SWS in mice. 
Typical examples of EEG, EMG and hypnograms of a mouse after the administration of 
saline (A) or A2AR PAM-1 (B). EEG signal of brain shows high amplitude and low 
frequency in SWS or low amplitude and high frequency in wake periods.   
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Figure 2.2 Intraperitoneal administration of A2AR PAM-1 increased the time spent 
and total amount of SWS, REM, and Wake in mice 
Time-courses (A) and total amounts (B) of SWS, REM sleep, and wakefulness in mice 
after intraperitoneal administration of saline or A2AR PAM-1. Data are presented as the 
mean ± SEM. *: p<0.05; **: p<0.01 compared with saline, assessed by ANOVA Tukey 
Test or unpaired Student’s t-test, (n=5/group) 
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Figure 2.3 Intraperitoneal administration of A2AR PAM-1 induced SWS in a dose-
dependent manner with an identical EEG power density as natural sleep. 
Dose-dependent changes in SWS time during 8 h after A2AR PAM-1 administration (A). 
EEG power density of SWS during 8 h after saline or A2AR PAM-1 administration (B). 
Data are presented as the mean ± SEM and assessed by ANOVA Tukey Test or unpaired 
Student’s t-test, (n=5/group) 
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Figure 2.4 Sleep architecture of mice after intraperitoneal administration of A2AR 
PAM-1.  
Episode number (A) and mean duration (B) of each stage after administration of saline or 
A2AR PAM-1. (C) Transitions between SWS (S), REM sleep (R) and wake (W) stages 
after administration of saline or A2AR PAM-1. Data are presented as the mean ± SEM. *: 
p<0.05; **: p<0.01, compared with saline, assessed by unpaired Student’s t-test, 
(n=5/group). 
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2.4 Summary & Conclusions 
Intraperitoneal administration of adenosine A2A receptors positive allosteric modulator, 
A2AR PAM-1 induced slow-wave sleep with a concomitant decrease of wakefulness in a 
dose-dependent manner following 8h. Moreover, EEG power density of SWS after 
administration of A2AR PAM-1 is identical to the control group.  It indicates that A2AR 
PAM-1 induces a physiological sleep but not an artificial sleep. i.p. administration of 
A2AR PAM-1 does not affect REM sleep and decreases the mean duration of the wake 
period without any effects on the mean duration of the SWS and REM sleep. 
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Chapter 3 
 
Sleep-inducing A2AR PAM-1’s dependency on the adenosine A2AR in mice. 
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3.1 Introduction 
Since A2AR PAM-1 induces slow-wave sleep in mice, its dependency on adenosine A2AR 
needed to clarify. To address this issue, we conducted an experiment in which A2AR 
antagonist suppressed A2AR PAM-1 SWS inducing effects. Moreover, we also tested the 
SWS inducing effects of A2AR PAM-1 on A2AR global knockout mice to confirm 
dependency of A2AR PAM-1 to A2AR in vivo.  
 
3.2 Materials and Methods 
 
3.2.1 Animals 
Male mouse lines on a C57BL/6 background, including wild-type and A2AR KO (Chen et 
al., 1999) mice, which were maintained at the International Institute of Integrative Sleep 
Medicine and weighing 21-27 g (10-15 weeks old), were used in the experiments. The 
animals were housed in an insulated and soundproof recording chamber that was 
maintained at an ambient temperature of 23 ± 0.5°C with a relative humidity of 50 ± 5% 
and an automatically controlled 12 h light/12 h dark cycle (light on at 8:00, illumination 
intensity ≈ 100 lux). All animals had free access to food and water. This study was 
performed in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the US National Institutes of Health (2011). Experimental 
protocols were in compliance with relevant Japanese and institutional laws and guidelines 
and approved by the University of Tsukuba animal ethics committee (protocol #14-322). 
Every effort was made to minimize the number of animals used as well as any pain and 
discomfort experienced by the animals. 
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3.2.2 Stereotaxic surgery for placement of EEG/EMG electrodes 
Mice were anesthetized with pentobarbital [50 mg·kg
-1
, intraperitoneal (i.p.)] and then 
placed in a stereotaxic apparatus. Electroencephalogram (EEG) and electromyogram 
(EMG) electrodes for polysomnographic recordings were chronically implanted in the 
mice (Oishi et al., 2016). The implant comprised two stainless steel screws (1 mm in 
diameter) inserted through the skull above the cortex (anteroposterior, +1.0 mm; left-
right, -1.5 mm from bregma or lambda) according to the atlas of Paxinos and Franklin 
(Paxinos and Franklin, 2004) that served as the EEG electrodes. Two insulated, stainless 
steel Teflon-coated wires were placed bilaterally into both trapezius muscles and served 
as the EMG electrodes. All electrodes were attached to a micro connector and fixed to the 
skull with dental cement.  
 
3.2.3 Vigilance state assessment by using EEG/EMG polygraphic recordings 
Ten days after surgery, the mice were individually housed in transparent barrels in an 
insulated soundproof recording chamber and connected to the EEG-EMG recording 
cables for 3 to 5 days of habituation before starting the polygraphic recordings. To 
evaluate the spontaneous sleep-wake cycle, each animal was recorded for 24 h beginning 
at 20:00, the onset of the dark period. The animals then entered the pharmacologic phase 
of the study in which sleep-wakefulness parameters were recorded for 36 h. The data 
collected during the first 24 h also served as baseline comparison data for the second 
experimental day. Cortical EEG/EMG recordings were amplified, filtered (EEG 0.5-30 
Hz; EMG 20-200 Hz), and digitized at a sampling rate of 128 Hz, and then recording 
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using data acquisition software SleepSign® (Kissei Comtec, Matsumoto, Japan). The 
vigilance states were classified offline in 10-s epochs into three stages, i.e., wakefulness, 
rapid eye movement (REM) sleep, and SWS by SleepSign® (ver 3.4) according to 
standard criteria (Oishi et al., 2016). As a final step, defined vigilance stages were 
examined visually, and corrected when necessary.  
 
3.2.4 Pharmacological treatment 
For control data, mice were injected with saline or vehicle (10 ml·kg-1 body weight, 
i.p.) at 22:00 or 21:30, respectively. A2AR PAM-1 was dissolved in saline immediately 
before use and administered intraperitoneally at 22:00 on the experimental day at a 
dose 75 mg·kg-1. ZM241385 (15 mg·kg-1, i.p.) was dissolved in vehicle (5% DMSO, 
5% Cremophor® EL in saline) and injected into C57BL/6J mice at 21:30. Mice were 
randomly assigned to groups that received control or drug injections.  
 
 
 
3.3 Results 
 
3.3.1 Sleep-inducing effect of A2AR PAM-1 was suppressed by blocking A2ARs 
We further investigated whether A2ARs mediate the sleep-inducing effect of A2AR PAM-
1. First, we pretreated wild-type mice with the selective A2AR antagonist ZM241385 (15 
mg·kg
-1
, i.p.) or vehicle 30 min before the A2AR PAM-1 injection at 22:00. The dose of 
ZM241385 was selected based on previous studies (El Yacoubi et al., 2000; Nakamura et 
al., 2016). In the presence of ZM241385, A2AR PAM-1 injection produced no significant 
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changes in SWS (Figure 3.1A), indicating that ZM241385 completely blocked the A2AR 
PAM-1–induced SWS. When we calculated the total amount of SWS for 4 h after the 
intraperitoneal injection of A2AR PAM-1 (Figure 3.1B), we found that it did not 
significantly alter the total amount of SWS after ZM241385 pretreatment. ZM241385 
pretreatment alone also had no significant effect on SWS compared with vehicle 
pretreatment. 
 
3.3.2 Sleep inducing effects of A2AR PAM-1 was abolished in A2AR-KO mice 
We then administered 75 mg·kg
-1
 A2AR PAM-1 (i.p.) into A2AR KO mice and their wild-
type littermates at 22:00. We observed no significant changes in SWS in the A2AR KO 
mice compared with saline treatment, whereas SWS was increased by 74.3 ± 12.0 min for 
6 h in wild-type littermates of A2AR KO mice (Figure 3.2A, B). Concomitantly, 
wakefulness was decreased in the wild-type littermates of A2AR KO mice, whereas 
neither REM sleep in these mice nor wakefulness and REM sleep in the KO mice were 
affected by intraperitoneal administration of 75 mg·kg
-1
 A2AR PAM-1 (Figure 3.3A-D). 
Baseline sleep and wake of knockout mice and their wild-type littermates prior to 
treatment was not significantly different between the saline and A2AR PAM-1 groups 
during the dark period (data not shown). These findings suggest that A2AR are necessary 
for A2AR PAM-1 to induce SWS.  
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Figure 3.1 A2AR antagonist suppressed sleep-inducing effect of A2AR PAM-1 in mice 
Time-courses (A) and total amount (B) of SWS in mice pretreated with vehicle or A2AR 
antagonist ZM 241385 after administration of saline or A2AR PAM-1. Data are presented 
as the mean ± SEM. *: p<0.05; compared with saline, assessed by ANOVA Tukey Test 
or unpaired Student’s t-test, (n=5/groups). 
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Figure 3.2 Sleep inducing effect of A2AR PAM-1 was abolished in A2AR-KO mice.   
Time courses (A) and total amount (B) of SWS in wild-type (top panels) or A2AR 
knockout mice (bottom panels) after administration of saline or A2AR PAM-1. Data are 
presented as the mean ± SEM. *: p<0.05; **: p<0.01; ***: p<0.001 compared with 
saline, assessed by ANOVA Tukey Test or unpaired Student’s t-test, (n=8/group). 
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Figure 3.3 REM sleep and wakefulness in wild type and A2AR knockout mice after 
intraperitoneal administration of A2AR PAM-1.  
Time courses (A and C) and total amount (B and D) of REM sleep (top panels) and 
wakefulness (bottom panels) wild type (A and B) and A2AR knockout mice (c and d). 
Data are presented as the mean ± SEM. *: p<0.05; **: p<0.01; ***: p<0.001, 
Compared with saline, assessed by ANOVA Tukey Test or unpaired Student’s t-test, 
(n=8/group). 
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3.4 Summary & Conclusions  
 
Slow-wave sleep-inducing effect of A2AR PAM-1 suppressed by A2AR antagonist, ZM 
241385. Furthermore, A2AR PAM-1 activity was abolished in A2AR-KO mice. These 
findings indicate that SWS inducing effects of A2AR PAM-1 depends on A2AR in mice. 
Besides that, A2AR PAM-1 did not alter the REM sleep profile of the mice.  
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CHAPTER 4 
 
Central administration of A2AR PAM-1 effects on slow-wave sleep in mice 
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4.1 Introduction 
 
Adenosine A2AR is widely expressing in the peripheral system. To confirm that SWS 
inducing-effect of A2AR PAM-1 is a brain-centric, we infused the A2AR PAM-1 into the 
lateral ventricular region of the brain via an implanted cannula controlled by the 
automatic pump system during the dark period. Moreover, the EEG power density of 
SWS and the sleep architecture of the animals were also analyzed during the infusion of 
A2AR PAM-1 in the dark period.  
 
4.2 Materials and Methods 
 
4.2.1 Animals 
Male mouse lines on a C57BL/6 background, including wild-type and A2AR KO (Chen et 
al., 1999) mice, which were maintained at the International Institute of Integrative Sleep 
Medicine and weighing 21-27 g (10-15 weeks old), were used in the experiments. The 
animals were housed in an insulated and soundproof recording chamber that was 
maintained at an ambient temperature of 23 ± 0.5°C with a relative humidity of 50 ± 5% 
and an automatically controlled 12 h light/12 h dark cycle (light on at 8:00, illumination 
intensity ≈ 100 lux). All animals had free access to food and water. This study was 
performed in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the US National Institutes of Health (2011). Experimental 
protocols were in compliance with relevant Japanese and institutional laws and guidelines 
and approved by the University of Tsukuba animal ethics committee (protocol #14-322). 
Every effort was made to minimize the number of animals used as well as any pain and 
discomfort experienced by the animals. 
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4.2.2 Stereotaxic surgery for placement of EEG/EMG electrode and infusion 
cannula  
Mice were anesthetized with pentobarbital [50 mg·kg
-1
, intraperitoneal (i.p.)] and then 
placed in a stereotaxic apparatus. Electroencephalogram (EEG) and electromyogram 
(EMG) electrodes for polysomnographic recordings were chronically implanted in the 
mice (Oishi et al., 2016). The implant comprised two stainless steel screws (1 mm in 
diameter) inserted through the skull above the cortex (anteroposterior, +1.0 mm; left-
right, -1.5 mm from bregma or lambda) according to the atlas of Paxinos and Franklin 
(Paxinos and Franklin, 2004) that served as the EEG electrodes. Two insulated, stainless 
steel Teflon-coated wires were placed bilaterally into both trapezius muscles and served 
as the EMG electrodes. All electrodes. For intracerebroventricular (i.c.v.) infusion of 
A2AR PAM-1, a stainless-steel cannula was inserted into mice during surgery 0.5 mm 
anterior and 1.6 mm lateral to bregma to a depth of 1.6 mm below the dura at an angle of 
20°, thus placing the cannula into the lateral ventricle. To ensure correct placement of 
cannula, a plastic tube filled with saline was attached to the infusion cannula; a drop in 
the meniscus indicated that the cannula tip was in the ventricle. During the experiments, 
the mice were infused continuously using an infusion pump with artificial cerebrospinal 
fluid into the lateral ventricle of the brain at a speed of 1 µl·h
-1
. Sleep-wakefulness states 
were monitored for a period of 36 h after infusion of each compound. Saline infusion 
recordings were obtained in each animal for 36 h, beginning at 20:00, which served as the 
control for the same animal. In the next experiment, A2AR PAM-1 (200 nmol·h
-1
) was 
infused into the lateral ventricle of the mouse brain for 12 h (20:00 to 8:00). 
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4.2.3 Vigilance state assessment by using EEG/EMG polygraphic recordings 
Ten days after surgery, the mice were individually housed in transparent barrels in an 
insulated soundproof recording chamber and connected to the EEG-EMG recording 
cables for 3 to 5 days of habituation before starting the polygraphic recordings. To 
evaluate the spontaneous sleep-wake cycle, each animal was recorded for 24 h beginning 
at 20:00, the onset of the dark period. The animals then entered the pharmacologic phase 
of the study in which sleep-wakefulness parameters were recorded for 36 h. The data 
collected during the first 24 h also served as baseline comparison data for the second 
experimental day. Cortical EEG/EMG recordings were amplified, filtered (EEG 0.5-30 
Hz; EMG 20-200 Hz), and digitized at a sampling rate of 128 Hz, and then recording 
using data acquisition software SleepSign® (Kissei Comtec, Matsumoto, Japan). The 
vigilance states were classified offline in 10-s epochs into three stages, i.e., wakefulness, 
rapid eye movement (REM) sleep, and SWS by SleepSign® (ver 3.4) according to 
standard criteria (Oishi et al., 2016). As a final step, defined vigilance stages were 
examined visually, and corrected when necessary.  
 
4.2.4 Pharmacological treatment 
For control data, mice were infused with saline only (1µl/h) between 20:00-08:00 
o’clock. A2AR PAM-1 was dissolved in saline immediately before use and infused into 
lateral ventricular between 20:00-08:00 o’clock on an experimental day at a 
concentration of 200 nmol·µl
-1
.  
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4.3 Results 
 
 
4.3.1 Intracerebroventricular administration of A2AR PAM-1 induces SWS in mice 
To elucidate whether the sleep-inducing effect of A2AR PAM-1 is mediated via A2ARs 
expressed in the brain, we infused A2AR PAM-1 into the lateral ventricle of wild-type 
mice at 200 nmol·h
-1
 during the dark period (20:00 to 8:00) and assessed EEG and EMG 
activity. Infusion with A2AR PAM-1 for 12 h increased the time spent in SWS 5 h after 
the infusion, resulting in a total SWS increase during the dark period of 141.6 ± 12.5 min 
compared with saline infusion (Figure 4.1A, B). Concomitantly, total wakefulness was 
decreased by 145.5 ± 15.8 min during a 12-h i.c.v. infusion of A2AR PAM-1, whereas 
REM sleep was not affected. 
 
4.3.2 Intracerebroventricular administration of A2AR PAM-1 does not affect EEG 
power density in SWS. 
The EEG activity in the frequency range of 0.5–25 Hz during SWS episodes was 
indistinguishable between mice treated with saline or A2AR PAM-1 (Figure 4.2). 
These data suggest that A2AR PAM-1 induces physiologic sleep rather than abnormal 
sleep via A2ARs that are likely expressed in the brain. 
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4.3.3 Intracerebroventricular administration of A2AR PAM-1 effects on sleep 
architecture of mice. 
Intracerebroventricular infusion of A2AR PAM-1 (200 nmol·h
-1
) into mice affected SWS 
and wake episode numbers during the dark period (Figure 4.3A).  SWS episode numbers 
lasting 0 to 29 s, 30 to 59 s, and 60 to 120 s increased by 267%, 196%, and 154%, 
respectively, and wake episode numbers lasting 0 to 29 s, 30 to 59 s, and 60 to 120 s also 
increased by 205%, 177%, and 137%, respectively, compared with saline infusion. On 
the other hand, episode numbers of REM sleep were not significantly affected by A2AR 
PAM-1 infusion (200 nmol·h
-1
, i.c.v.). The mean duration of wake episodes decreased by 
72% compared with the saline-infused group, but mean episode duration of the SWS and 
REM sleep did not significantly change after A2AR PAM-1 (200 nmol·h
-1
, i.c.v.) 
administration (Figure 4.3B). A2AR PAM-1 (200 nmol·h
-1
, i.c.v.) increased the number 
of transitions between SWS and wakefulness by 148%, and from wakefulness to SWS by 
128% compared with the saline-infused group (Figure 4.3C).  
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Figure 4.1 Intracerebroventricular infusion of A2AR PAM-1 induced SWS in mice. 
The time-courses (A) and (B) total amount of SWS, REM sleep, and wakefulness in mice 
after intracerebroventricular infusion of saline or A2AR PAM-1. Data are presented as the 
mean ± SEM. *: p<0.05; **: p<0.01; ***: p<0.001 compared with saline, assessed by 
ANOVA Tukey Test or Student’s t-test,  (n=5/group).  
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Figure 4.2 EEG power density of SWS during the infusion of saline or A2AR PAM-1. 
Intracerebroventricular infusion of A2AR PAM-1 does not affect the EEG power density 
of sleep (n=5/group). 
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Figure 4.3 Sleep architecture of mice during intracerebroventricular infusion of 
A2AR PAM-1.  
Episode number (A) and mean duration (B) of each stage after infusion of saline or A2AR 
PAM-1. (C) Transitions between SWS (S), REM sleep (R) and wake (W) stages after 
infusion of saline or A2AR PAM-1. Data are presented as the mean ± SEM. *: p<0.05; **: 
p<0.01, ***: p<0.001, compared with saline, assessed by Student’s t-test, (n=5/group). 
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4.4 Summary & Conclusions 
 
Intracerebroventricular infusion of A2AR PAM-1 robustly increased the SWS with 
concomitantly decreasing the wakefulness at the dark period. REM sleep profile of the 
mice did not affect by the infusion of A2AR PAM-1 at the dark period. In addition, EEG 
power density of SWS showed an identical rhythm as a control group during the infusion 
of the A2AR PAM-1. Moreover, A2AR PAM-1 infusion at the dark period increased the 
SWS episode numbers and decreased the mean duration of the wake stages. It also 
significantly changed the stage transition number between SWS to wake or wake to SWS.  
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Chapter 5 
 
The effects of A2AR PAM-1 on body temperature and cardiovascular function  
 73 
5.1. Introduction 
 
Adenosine A2A receptors are also expressing in cardiovascular systems. There are 
growing bodies of reports shows that A2AR activation by A2AR agonist causes 
hypotension. Therefore, we conducted a series of experiments to investigate the effects of 
the A2AR PAM-1 on the cardiovascular function. After i.p. administration of A2AR PAM-
1, we checked the blood pressure of the mice by using the tail-cuff method, heart rhythm 
of the mice by using intracardiac electrocardiogram and heart rate by using telemetry 
method. Besides that, we also measured the body temperature of animals after i.p. 
administration of A2AR PAM-1. 
 
5.2. Materials and Methods 
 
 
5.2.1 Blood pressure and heart rate measurement  
The blood pressure of the mice was measured using the tail-cuff method with a BP-98A 
blood pressure device (Softron, Tokyo, Japan).  The same time period (13:00 – 16:00) 
was selected for testing the blood pressure of each mouse (9-12 weeks old) to avoid 
normal daily variations in blood pressure. Five consecutive days were used to habituate 
the mice to the device. To optimize cardiovascular circulation, mice were wrapped in a 
cotton sheet and, except for the tail, maintained at 37°C within a cylinder heater. A 
programmable sensor with an inflatable balloon attached to a tail cuff was used to 
monitor tail pulse waves and measure blood pressure when the pulse waves were stable 
and rhythmic. Blood pressure measurement was read and recorded by the software. After 
five consecutive training days, mice were randomly assigned to one of three groups and 
injected with saline (10 ml·kg
-1
, i.p.), A2AR PAM-1 (75 mg·kg
-1
, i.p.) or CGS 21680 (1 
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mg·kg
-1
, i.p.). Blood pressure was measured at 30 min, 1 h 30 min, and 2 h 30 min after 
injection (at each time-point, 20 readings for each mouse were collected). After testing, 
the mice were gently picked up by the tail and gently returned to their cages.  
 
The heart rate of the mice was measured by telemetry. Mice were anesthetized with 
ketamine hydrochloride (80 mg·kg
-1
, i.p.) and xylazine hydrochloride (8 mg·kg
-1
, i.p.) 
and a PhysioTel F20-ETA mouse telemetry transmitter (Data Science International, St. 
Paul, MN) was placed in the midline of the mouse back and fixed with surgical sutures. 
The negative (white) electrode was placed in the trapezius muscle, while the positive 
(red) electrode was sutured to a muscle in the back opposite the xiphoid process. Each 
mouse was singly housed in a cage after surgery with a distance of at least 1 m between 
cages to avoid interference between telemetry transmitters. After 7 days of recovery, the 
mice were randomly assigned to one of three groups and injected with saline (10 ml·kg
-1
, 
i.p.), A2AR PAM-1 (75 mg·kg
-1
, i.p.), or CGS 21680 (1 mg·kg
-1
, i.p.). The transmitted 
cardiovascular signal was analyzed for 2 h after the injections using Data Science 
International software.  
 
5.2.2 Heart rhythm measurement  
The cardiac rhythm of mice was measured by electrocardiography (ECG). Mice were 
anesthetized with ketamine hydrochloride (80 mg·kg
-1
, i.p.) and xylazine hydrochloride 
(8 mg·kg
-1
, i.p.) and fixed with needles on a styrofoam platform. Mice were then gently 
pushed into a position where the two front paws and the left rear paw are in contact with 
25-gauge needles that served as ECG electrodes. For intracardiac electrography, the 
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throat of the mice was opened and the internal jugular vein was isolated to insert a 
catheter along the course of the vein to the right atrium. Electrographic signals were 
5.000-10.000-fold amplified and filtered (0.5-250 Hz) with an AC-601G system (Nihon 
Kohden, Tokyo, Japan). The same time period (10:00 – 12:00) was selected for testing 
the heart rhythm to avoid normal daily variations in the cardiac rhythm. Mice were 
randomly assigned to groups that received A2AR PAM-1 (75 mg·kg
-1
, i.p.) or CGS 21680 
(1 mg·kg
-1
, i.p.) injections. After recording the baseline for 1-2 minutes, mice were 
injected with drugs and recording continued for 30 minutes. The data were analyzed 
using LabChart Pro software (ADInstruments, Dunedin, New Zealand). 
  
5.2.3  Body temperature measurement  
The core body temperature of mice was measured using Thermochron iButtons (KN 
Laboratories, Osaka, Japan). iButtons were programmed to monitor core body 
temperature every 5 min for 14 consecutive days beginning at the end of the recovery 
period. The mice were anesthetized with pentobarbital (50 mg·kg-1, i.p.), and the skin of 
the abdomen was shaved and cleaned with 70% ethanol. A longitudinal, 2-cm incision 
was made along the midline. One iButton cleaned with 70% ethanol was placed in the 
abdominal cavity and the incision was closed with nylon sutures. The mice were housed 
individually in cages after surgery under 12:12 light/dark cycles and experiments were 
conducted after a 10-day recovery period.  iButtons were removed from the animals after 
cervical dislocation euthanasia and RhManager software (KN Laboratories, Osaka, 
Japan) was used to collect the recorded data from the iButtons. 
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5.3 Results 
 
5.3.1 Intraperitoneal administration of A2AR PAM-1 does not affect blood pressure 
and hear rate in mice 
A2AR agonists evoke cardiovascular effects (Hutchison et al., 1989; Kirkup et al., 1998; 
Nekooeian and Tabrizchi, 1996). We therefore tested the effect of intraperitoneal 
administration of A2AR PAM-1 on blood pressure and heart rate in wild-type mice. First, 
we measured blood pressure in mice 30, 90, and 150 min after intraperitoneal injection of 
75 mg·kg
-1
 A2AR PAM-1 or 1 mg·kg
-1
 of the A2AR agonist CGS 21680 using an 
electrosphygmomanometer (Figure 5.1). The dose of the A2AR agonist CGS 21680 was 
selected based on previous studies in mice (Carvalho et al., 2017; Nakav et al., 2008; 
Ohta and Sitkovsky, 2001). Compared with saline treatment, the systolic, and diastolic 
blood pressures were significantly decreased for up to 90 min after injecting the A2AR 
agonist CGS 21680 and returned to normal levels within 150 min after the injection. In 
contrast, blood pressure was not changed after intraperitoneal administration of A2AR 
PAM-1 (75 mg·kg
-1
) at 30, 90, or 150 min after treatment. In addition, we measured the 
heart rate of mice after intraperitoneal injection of 75 mg·kg
-1
 A2AR PAM-1 or 1 mg·kg
-1
 
A2AR agonist CGS 21680 using the telemetry implants (Figure 5.2). The heart rate of the 
mice increased after intraperitoneal administration of the A2AR agonist CGS 21680, 
whereas the heart rate was not affected by injection of 75 mg·kg
-1
 A2AR PAM-1.  
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5.3.2 Intraperitoneal administration of A2AR PAM-1 does not affect heart rhythm in 
mice 
We monitored the heart rhythm in anesthetized mice after intraperitoneal administration 
of 75 mg·kg
-1
 of A2AR PAM-1 or 1 mg·kg
-1
 of A2AR agonist CGS 21680 using 
intracardiac EGM. We observed sinus arrhythmia in mice after intraperitoneal 
administration of A2AR agonist CGS 21680, whereas injection of 75 mg·kg
-1
 A2AR PAM-
1 did not cause abnormalities of the cardiac rhythm (Figure 5.3A-C). 
 
 
 
 
 
5.3.2 Intraperitoneal administration of A2AR PAM-1 does not affect body 
temperature in mice 
We also measured the effect of intraperitoneal administration of 75 mg·kg
-1
 A2AR PAM-1 
or 1 mg·kg
-1
 of the A2AR agonist CGS 21680 (as positive control) on the body 
temperature of mice during the dark period (Figure 5.4). Whereas CGS 21680 strongly 
decreased the body temperature for almost 2 h (t(10)=3.68, P=0.0042 at 22:15, t(10)=10.48, 
P<0.0001 at 23:15, t(10)=2.33, P=0.041 at 00:05 vs. saline injected group, unpaired t-test), 
A2AR PAM-1 did not affect the body temperature of the mice. These data suggest that 
A2AR PAM-1 induces physiological sleep independent of the body temperature. 
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Figure 5.1 A2AR PAM-1 does not affect blood pressure in mice.  
Blood pressure after A2AR PAM-1 and CGS 21680 injection in mice. Data are presented 
as the mean ± SEM. **: p<0.01 vs. saline, Student’s t-test. (n=6/group). Abbreviations 
used: CGS 21680, selective adenosine A2A receptor agonist; SBP, systolic blood 
pressure; DBP, Diastolic blood pressure. 
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Figure 5.2 A2AR PAM-1 does not affect heart rate in mice 
 
Heart rate of mice after injection of saline, A2AR PAM-1, or CGS 21680, assessed by the 
telemetry implants. Data are presented as the mean ±SEM. *: p<0.05 vs. Saline, Student’s 
t-test. (n=5/group). CGS 21680, selective adenosine A2A receptor agonist.  
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Figure 5.3 A2AR PAM-1 does not affect heart rhythm in mice.  
Typical heart rhythm profiles of mice without treatment (A) or after administration of 
A2AR PAM-1 (B) or CGS 21680 (C). Red and blue left/right arrows in the right panel 
indicate sinus arrhythmia.  
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Figure 5.4 A2AR PAM-1 does not affect body temperature in mice.  
Body temperature of mice after intraperitoneal administration of saline, A2AR PAM-1 or 
CGS 21680. Data are presented as the mean ±SEM. **: p<0.01 vs. Saline, Student’s t-
test. (n=6/group).  
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5.4 Summary & Conclusions 
 
As like we expected, A2AR potent agonist CGS 21680 was significantly decreased the 
blood pressure of the mice during two hours after injection and it also caused irregular 
heart rhythm or sinus arrhythmia. On the other hand, A2AR PAM-1 did not alter the blood 
pressure and heart rhythm of the mice compared to the control groups. Moreover, CGS 
21680 also significantly decreased the heart rate for two hours after injection but A2AR 
PAM-1 did not cause any significant change during this time period. Besides that, 
whereas CGS 21680 strongly decreased body temperature for almost 2 hours, A2AR 
PAM-1 did not affect the body temperature of the mice. These data suggest that A2AR 
PAM-1 induces physiological sleep independent of the body temperature. 
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General Discussions  
 84 
 
Our observations suggest that enhancing A2AR signaling by intraperitoneal administration 
of A2AR PAM-1 induces SWS without cardiovascular effects in mice. Therefore, A2AR-
modulating compounds may provide safe options for the treatment of insomnia and poor-
quality sleep.  
 
Over the past century, several putative hypnogenic substances implicated in the sleep 
homeostatic process have been identified, including prostaglandin D2 (Qu et al., 2006b), 
cytokines (Krueger et al., 1984b), anandamide (García-García et al., 2009b), urotensin II 
peptide (Huitron-Resendiz et al., 2005), and adenosine (Porkka-Heiskanen et al., 1997). 
Adenosine represents a state of relative energy deficiency: ATP depletion positively 
correlates with an increase in extracellular adenosine levels (Kalinchuk et al., 2003) and 
positively associates with sleep (Porkka-Heiskanen et al., 1997). Adenosine levels in 
samples collected from several brain areas of cats during spontaneous sleep-wake cycles 
by in vivo microdialysis were higher during SWS than during wakefulness for all probed 
brain areas (Porkka-Heiskanen et al., 1997). The observation in animals that adenosine 
levels are elevated during prolonged wakefulness may explain why an allosteric 
modulator could effectively enhance the sleep-inducing effect of endogenous adenosine 
in the brain. On the other hand, adenosine is absent or its concentration is too low in the 
cardiovascular system under physiologic conditions to affect blood pressure and heart 
function after administration of an allosteric modulator of A2AR. 
 
Medicinal chemistry for A2ARs has been widely developed in recent decades for use in 
myocardial perfusion imaging and the treatment of inflammation and neuropathic pain 
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(de Lera Ruiz et al., 2014). Several A2AR agonists that entered clinical trials elicited 
undesirable side effects, however, thus precluding their further development. On the other 
hand, allosteric modulators bind at a distinct site other than the natural ligand binding site 
(i.e., the orthosteric site) and exert their effects only in the presence of the orthosteric 
ligand (Wenthur et al., 2014). As a consequence, an allosteric modulator mimics the 
activity duration of the natural ligand and thus the pharmacologic response of an 
allosteric modulator more closely resembles the natural physiologic activity of the 
receptor than is possible with a synthetic agonist. Because efforts to evoke pharmacologic 
A2AR responses have focused almost exclusively on the use of orthosteric ligands, 
however, the possibility that A2AR responses, especially in the brain, can be fine-tuned 
using allosteric modulators has received very little attention (Göblyös and Ijzerman, 
2009).  
 
Moreover, it is widely accepted that the basic adenosine scaffold must be maintained in 
an A2AR agonist (Fredholm et al., 2011). Thus, the development of adenosine analogs for 
treating the central nervous system, including sleep induction for treating insomnia, is 
restricted by the poor transport of these drugs through the brain endothelial cells, which 
are connected by tight junctions to establish a blood-brain barrier (BBB) (Pardridge et al., 
1994). In contrast, A2AR PAM-1, when administered intraperitoneally, exhibits a sleep-
inducing effect that is likely mediated by A2ARs in the brain and thus appears to cross the 
BBB. Small lipophilic monocarboxylates like A2AR PAM-1 likely pass through the BBB 
by passive diffusion or via a monocarboxylate transport system (Tsuji, 2005). Therefore, 
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allosteric modulation of A2ARs has the potential to cause pharmacologic effects in the 
central nervous system after systemic administration, resulting in good quality sleep. 
 
Our study did not investigate how and where the A2AR PAM-1 binds at the receptor to 
exert its allosteric effect. Therefore, an important next step will be to examine allosteric 
interactions of A2AR PAM-1 and the receptor using binding assays and crystal structure 
analysis. With respect to the latter, the crystal structure of the human A2AR bound to a 
bitopic antagonist revealed a potential allosteric pocket (Sun et al., 2017) and another 
study suggested that a sodium ion binding site could be exploited for allosteric 
modulation of A2AR (Gutiérrez-de-Terán et al., 2013). Moreover, to solidify the sleep 
enhancing effect of the A2AR PAM-1, it may be necessary to test the A2AR PAM-1 in 
mice at the time of normal sleep onset, i.e., A2AR PAM-1 administration at the onset of 
the light period, or in an animal model of insomnia, for example, a mouse model 
mimicking the human first-night effect  (Xu et al., 2014). 
 
Due to work schedules and expectations, lifestyle choices, pre-existing medical 
conditions, or aging, people are coping with an increasingly wide range of sleep 
problems, including difficulties with falling and staying asleep, waking up too early, and 
poor-quality ("non-restorative") sleep. Deficiencies in sleep cause significant social 
losses due to increased prevalence of mood disorders, lead to decreased economic 
productivity, and are linked to traffic and work-related accidents due to excessive 
daytime sleepiness (Groeger et al., 2004; Saddichha, 2010; Sutton et al., 2001). 
Insufficient sleep is not only by itself a major problem in modern society, but is also an 
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established risk factor for obesity, diabetes, heart disease, and other lifestyle diseases 
(Colten et al., 2006). Moreover, psychiatric illnesses, especially anxiety and mood 
disorders, are long recognized to be a frequent cause of insomnia (Okuji et al., 2002).  
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Conclusions 
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The findings of our study indicate that enhancing A2AR signaling promotes SWS without 
cardiovascular effects. Therefore, small molecules that allosterically modulate A2ARs 
could help people with sleep problems to fall asleep and thus also be a potential treatment 
for psychiatric disorders. 
Our study was conducted in mice which are the most commonly used model organism in 
human disease. The mouse is, however, not particularly reliable at predicting the outcome 
of studies in humans, mostly due to limited genetic diversity associated with common 
laboratory mice. Therefore, many obstacles in generating a novel drug for the treatment 
of insomnia in humans remain.  
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